|
|
Vaccine Detail
|
alpha-GalCer-AuNP-MUC1-Tn Vaccine |
| Vaccine Information |
- Vaccine Name: alpha-GalCer-AuNP-MUC1-Tn Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Conjugate vaccine
- Status: Research
- Host Species for Licensed Use: Mouse
- Antigen: MUC1 (Liu et al., 2021)
- Immunization Route: subcutaneous injection
- Description: A conjugate vaccine containing MUC1-Tn tumor-associated glycopeptide antigen and alpha-galactosylceramide (alpha-GalCer) adjuvant, both covalently conjugated to gold nanoparticles (AuNPs) as a multivalent carrier, with potential antineoplastic activity. Vaccination with alpha-GalCer-AuNP-MUC1-Tn vaccine stimulates both humoral and CTL responses against MUC1-expressing tumor cells via iNKT cell activation through the CD1d pathway. MUC1 antigen, a transmembrane glycoprotein overexpressed in an aberrant glycosylated form in various cancers including breast, pancreas, lung and colon, is used as the tumor-associated antigen. The optimal 2:1 MUC1: alpha-GalCer formulation elicited high antibody titers (1:12,800), 54% complement-dependent cytotoxicity (CDC) against MCF-7 cells, a Th1-biased immune response (IgG2a/IgG1 >1), elevated IL-4/IFN-y, enhanced DC maturation with increased IL-6/IL-12, and increased CD8+ T cell tumor infiltration, resulting in significant tumor growth inhibition in a B16-MUC1 melanoma model. In contrast, unconjugated MUC1+alpha-GalCer mixture showed minimal immune response due to NKT cell anergy (Liu et al., 2021).
|
| Host Response |
|
|
| References |
Liu et al., 2021: Liu Y, Wang Z, Yu F, Li M, Zhu H, Wang K, Meng M, Zhao W. The Adjuvant of α-Galactosylceramide Presented by Gold Nanoparticles Enhances Antitumor Immune Responses of MUC1 Antigen-Based Tumor Vaccines. International journal of nanomedicine. 2021; 16; 403-420. [PubMed: 33469292].
|
|
